2 Result: Pharvaris
Pharvaris Gains Momentum, Avalo Therapeutics and FibroGen Suffer Setbacks
June 26th, 2023
Shares of Pharvaris N.V. (Nasdaq: PHVS) surged over 10% in pre-market trading after the clinical-stage company announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application f. Read more
Pharvaris: Potential On-Demand HAE Treatment; Novartis Is To Takeover Chinook Therapeutics
June 12th, 2023
Pharvaris N.V. (Nasdaq: PHVS) released data from their Phase 2 study, RAPIDe-1, evaluating the on-demand treatment of hereditary angioedema (HAE) attacks with PHVS416 (deucrictibant immediate-release capsules). The study showed that treatment with. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Treasury Targets Global Scam Networks and the Corporate Infrastructure That Enables Them
November 06th, 2026FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
November 05th, 2026New Details Emerge in Amazon Ads Auction-Rigging Case
November 05th, 2026November 02nd, 2026
Member Login